The Developing Regorafenib Eye drops for neovascular Age‐related Macular degeneration (DREAM) study: an open‐label phase II trial-Reference-Cited by-同舟云学术

The Developing Regorafenib Eye drops for neovascular Age‐related Macular degeneration (DREAM) study: an open‐label phase II trial

Published:2018-11-25 Issue:2 Volume:85 Page:347-355
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Joussen Antonia M.¹,Wolf Sebastian²,Kaiser Peter K.³,Boyer David⁴⁵,Schmelter Thomas⁶,Sandbrink Rupert⁶⁷,Zeitz Oliver¹⁶,Deeg Gesa⁶,Richter Annett⁶,Zimmermann Torsten⁶,Hoechel Joachim⁶,Buetehorn Ulf⁶,Schmitt Walter⁶,Stemper Brigitte⁶⁸,Boettger Michael K.⁶⁹^ORCID

Affiliation:

1. Department of OphthalmologyCharité – University Medicine Berlin Berlin Germany

2. Bern Photographic Reading Center and Department of Ophthalmology, Inselspital, University HospitalUniversity of Bern Bern Switzerland

3. Cole Eye Institute Cleveland OH USA

4. Retina‐Vitreous Associates Medical Group Beverly Hills CA USA

5. USC/Keck School of Medicine Los Angeles CA USA

6. Bayer AG, Division Pharma Berlin and Wuppertal Germany

7. Department of NeurologyHeinrich‐Heine University Düsseldorf Germany

8. Department of NeurologyUniversity Erlangen‐Nürnberg Erlangen Germany

9. Department of Sports MedicineBergische Universität Wuppertal Germany

Funder

Bayer AG, Germany

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13794

Reference34 articles.

1. Vascular endothelial growth factor: Biology and therapeutic applications

2. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor;Baffi J;Invest Ophthalmol Vis Sci,2000

3. Vascular endothelial growth factor and ocular neovascularization;Miller JW;Am J Pathol,1997

4. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

5. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I Study of Tivozanib Eye Drops in Healthy Volunteers and Patients with Neovascular Age-Related Macular Degeneration;Ophthalmology Science;2024-11

2. Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration;Archives of Pharmacal Research;2024-06

3. Drug-like properties of tyrosine kinase inhibitors in ophthalmology: Formulation and topical availability;International Journal of Pharmaceutics;2024-04

4. Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment;Progress in Retinal and Eye Research;2024-03

5. Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases;European Journal of Medicinal Chemistry;2023-09